SOPHiA GENETICS (SOPH) said Monday it expanded its collaboration with AstraZeneca (AZN) to deploy the MSK-ACCESS liquid biopsy testing application to 30 clinical institutions globally within the year.
The test is designed to detect actionable genomic alterations from a single blood draw, analyzing circulating tumor DNA to aid in real-time cancer monitoring and treatment selection, the company said.
The expanded roll-out will allow the two companies to further understand how liquid biopsy testing can complement solid tissue testing, SOPHiA said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.